Novo Holdings co-leads Hemab’s US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders

– Novo Holdings created Hemab from inception and now co-leads significant financing with Nordic and US investors
– Financing to advance pipeline of bispecific and monoclonal antibodies with prophyla… Read full article

Leave a comment

Your email address will not be published. Required fields are marked *